Please login to the form below

Not currently logged in
Email:
Password:

Astellas poaches new oncology head from Takeda

Claire Thom is named senior VP of global oncology development

Astellas Claire ThomDr Claire Thom has left her role at Takeda to join rival Japanese pharma company Astellas as senior VP of global oncology development.

Dr Thom was most recently senior VP portfolio management, drug development management and strategic business operations at Millennium, the oncology-focused subsidiary of Takeda.

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

At Millennium Dr Thom will have worked on Velcade, a drug co-developed with Johnson & Johnson (J&J) that is used in blood cancer.

"We're thrilled that Claire is joining our experienced oncology team at Astellas," said Dr Sef Kurstjens, chief medical officer of Astellas.

“We believe that her unique background and varied experience, along with her approach to leadership and management will support our mission to become a global category leader in oncology."

Prior to joining Millennium, Dr Thom served for several years at Takeda itself, including holding responsibility for the oversight and implementation of the global therapeutic area strategies for the company's oncology, urology and gynaecology franchises.

14th August 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...